Alvotech Sa (ALVO)

$13.5

Market is closed - opens 7 PM, 20 May 2024

Insights on Alvotech Sa

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 4.39M → 53.39M (in $), with an average increase of 71.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 189.32M → -276.55M (in $), with an average decrease of 123.2% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 72.3% return, outperforming this stock by 9.3%

Performance

  • $13.30
    $13.52
    $13.50
    downward going graph

    1.48%

    Downside

    Day's Volatility :1.63%

    Upside

    0.15%

    downward going graph
  • $6.70
    $18.00
    $13.50
    downward going graph

    50.37%

    Downside

    52 Weeks Volatility :62.78%

    Upside

    25.0%

    downward going graph

Returns

PeriodAlvotech SaSector (Health Care)Index (Russel 2000)
3 Months
-15.47%
0.5%
0.0%
6 Months
47.7%
14.1%
0.0%
1 Year
63.04%
11.9%
0.0%
3 Years
20.64%
18.7%
-20.0%

Highlights

Market Capitalization
3.7B
Book Value
- $3.49
Earnings Per Share (EPS)
-2.43
Wall Street Target Price
16.5
Profit Margin
0.0%
Operating Margin TTM
-134.68%
Return On Assets TTM
-23.45%
Return On Equity TTM
0.0%
Revenue TTM
93.4M
Revenue Per Share TTM
0.41
Quarterly Revenue Growth YOY
115.5%
Gross Profit TTM
20.9M
EBITDA
-319.0M
Diluted Eps TTM
-2.43
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.5
EPS Estimate Next Year
0.06
EPS Estimate Current Quarter
0.04
EPS Estimate Next Quarter
-0.08

Analyst Recommendation

Buy
    58%Buy
    41%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Alvotech Sa(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
5
4
3
Sell
00
1
1

Analyst Forecast

What analysts predicted

Upside of 22.22%

Current $13.50
Target $16.50

Company Financials

FY19Y/Y Change
Revenue
31.9M
-
Net Income
-209.9M
-
Net Profit Margin
-657.55%
-
FY20Y/Y Change
Revenue
66.6M
↑ 108.71%
Net Income
-170.0M
↓ 18.98%
Net Profit Margin
-255.26%
↑ 402.29%
FY21Y/Y Change
Revenue
36.8M
↓ 44.8%
Net Income
-101.5M
↓ 40.31%
Net Profit Margin
-276.04%
↓ 20.78%
FY22Y/Y Change
Revenue
83.0M
↑ 125.79%
Net Income
-513.6M
↑ 405.97%
Net Profit Margin
-618.55%
↓ 342.51%
FY23Y/Y Change
Revenue
91.4M
↑ 10.12%
Net Income
-551.7M
↑ 7.43%
Net Profit Margin
-603.42%
↑ 15.13%
Q3 FY22Q/Q Change
Revenue
19.1M
↓ 51.97%
Net Income
-8.6M
↓ 92.0%
Net Profit Margin
-45.15%
↑ 225.84%
Q4 FY22Q/Q Change
Revenue
15.9M
↓ 16.74%
Net Income
-276.2M
↑ 3110.65%
Net Profit Margin
-1.7K%
↓ 1695.77%
Q1 FY23Q/Q Change
Revenue
15.9M
↑ 0.0%
Net Income
-276.2M
↑ 0.0%
Net Profit Margin
-1.7K%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
4.4M
↓ 72.32%
Net Income
189.3M
↓ 168.55%
Net Profit Margin
4.3K%
↑ 6052.6%
Q3 FY23Q/Q Change
Revenue
17.8M
↑ 305.12%
Net Income
-188.3M
↓ 199.47%
Net Profit Margin
-1.1K%
↓ 5370.31%
Q4 FY23Q/Q Change
Revenue
53.4M
↑ 200.13%
Net Income
-276.6M
↑ 46.85%
Net Profit Margin
-517.99%
↑ 540.64%
FY20Y/Y Change
Total Assets
474.4M
-
Total Liabilities
1.3B
-
FY21Y/Y Change
Total Assets
598.0M
↑ 26.04%
Total Liabilities
733.6M
↓ 45.32%
FY22Y/Y Change
Total Assets
828.4M
↑ 38.54%
Total Liabilities
1.4B
↑ 89.87%
FY23Y/Y Change
Total Assets
950.1M
↑ 14.68%
Total Liabilities
1.9B
↑ 35.16%
Q3 FY22Q/Q Change
Total Assets
683.1M
↓ 11.8%
Total Liabilities
960.4M
↓ 10.31%
Q4 FY22Q/Q Change
Total Assets
895.5M
↑ 31.08%
Total Liabilities
1.6B
↑ 61.53%
Q1 FY23Q/Q Change
Total Assets
895.5M
↑ 0.0%
Total Liabilities
1.6B
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
910.7M
↑ 1.7%
Total Liabilities
1.4B
↓ 10.45%
Q3 FY23Q/Q Change
Total Assets
958.8M
↑ 5.29%
Total Liabilities
1.6B
↑ 16.59%
Q4 FY23Q/Q Change
Total Assets
950.1M
↓ 0.91%
Total Liabilities
1.9B
↑ 16.23%
FY19Y/Y Change
Operating Cash Flow
-88.5M
-
Investing Cash Flow
-12.9M
-
Financing Cash Flow
116.4M
-
FY20Y/Y Change
Operating Cash Flow
-74.3M
↓ 16.1%
Investing Cash Flow
-16.9M
↑ 31.28%
Financing Cash Flow
55.4M
↓ 52.39%
FY21Y/Y Change
Operating Cash Flow
-228.2M
↑ 207.11%
Investing Cash Flow
-40.6M
↑ 140.39%
Financing Cash Flow
254.8M
↑ 359.97%
FY22Y/Y Change
Operating Cash Flow
-312.4M
↑ 36.91%
Investing Cash Flow
-63.5M
↑ 56.37%
Financing Cash Flow
424.9M
↑ 66.74%
Q3 FY22Q/Q Change
Operating Cash Flow
-106.9M
↑ 3.17%
Investing Cash Flow
-11.6M
↓ 44.28%
Financing Cash Flow
3.0M
↓ 98.74%
Q4 FY22Q/Q Change
Operating Cash Flow
-86.1M
↓ 19.4%
Investing Cash Flow
-10.5M
↓ 9.47%
Financing Cash Flow
147.2M
↑ 4802.96%
Q1 FY23Q/Q Change
Operating Cash Flow
-86.1M
↑ 0.0%
Investing Cash Flow
-11.4M
↑ 8.42%
Financing Cash Flow
147.2M
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-41.9M
↓ 51.39%
Investing Cash Flow
-11.4M
↑ 0.0%
Financing Cash Flow
-2.7M
↓ 101.86%

Technicals Summary

Sell

Neutral

Buy

Alvotech Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alvotech Sa
Alvotech Sa
4.73%
47.7%
63.04%
20.64%
20.64%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
7.36%
30.03%
49.98%
51.68%
85.56%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
4.67%
3.15%
0.35%
14.84%
14.84%
Zoetis Inc.
Zoetis Inc.
13.68%
-1.14%
-3.15%
2.32%
70.28%
Viatris Inc.
Viatris Inc.
-1.26%
15.95%
17.18%
-31.59%
-32.8%
Catalent, Inc.
Catalent, Inc.
-0.77%
38.67%
72.28%
-44.82%
22.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alvotech Sa
Alvotech Sa
55.96
NA
NA
-0.5
0.0
-0.23
NA
-3.49
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
38.56
38.56
0.44
4.12
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.86
28.86
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
33.47
33.47
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.37
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alvotech Sa
Alvotech Sa
Buy
$3.7B
20.64%
55.96
0.0%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.3B
85.56%
38.56
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.2B
14.84%
28.86
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$79.3B
70.28%
33.47
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.1B
-32.8%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.0B
22.04%
211.02
-28.44%

Company Information

alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a

Organization
Alvotech Sa
Employees
999
CEO
Mr. Faysal Kalmoua
Industry
Services

Discover More

FAQs